Terminated PHASE2 INTERVENTIONAL 1-arm NCT03585062

Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer

Clinical Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin in Patients With Unresectable Locally Advanced Pancreatic Cancer

Sponsor: Zhejiang Provincial People's Hospital

Conditions Neoadjuvant Chemotherapy Pancreatic Cancer

Interventions Paclitaxel-albumin S1,

Updated 8 times since 2018 Last updated: Jan 6, 2021 Started: Nov 20, 2017 Primary completion: Jul 1, 2019 Completion: Jul 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The paclitaxel-albumin halt production.

Listed as NCT03585062, this PHASE2 trial focuses on Neoadjuvant Chemotherapy and Pancreatic Cancer and remains terminated or withdrawn. Sponsored by Zhejiang Provincial People's Hospital, it has been updated 8 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Feb 2021 — Jul 2024 [monthly]

Terminated PHASE2

Status: Unknown Status → Terminated
Jan 2021 — Feb 2021 [monthly]

Unknown Status PHASE2
Sep 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 3 earlier versions

Aug 2020 — Sep 2020 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Sep 2018 — Aug 2020 [monthly]

Recruiting PHASE2
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE2

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhejiang Provincial People's Hospital

Data source: Zhejiang Provincial People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hanzhou, China